At Foley’s sixth annual National Directors Institute on March 8, 2007 in Chicago, “Update from the PCAOB” was a featured breakout session focusing on a number of issues relating to the public company audit process. The discussion focused on items that might be of interest to audit committee members and directors of public companies. The panel prefaced the presentation with the disclaimer that the views expressed by the panel members are solely their own and not necessarily those of the Public Company Accounting Oversight Board (PCAOB), its members or its staff. Daniel L. Goelzer, PCAOB board member, and Jarett Decker, Deputy Director, Chief Trial Counsel, served on the panel.
Related Insights
20 December 2024
Health Care Law Today
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.
20 December 2024
Manufacturing Industry Advisor
Christmas Came Early: Justice Delivered in Supplier Dispute Over Unjust Enrichment
The AirBoss saga continues… This holiday season, AirBoss Flexible Products Co. received a monumental legal victory, righting a costly wrong in MSSC, Inc. v. AirBoss.
19 December 2024
Health Care Law Today
HIPAA Reproductive Health Care Amendments: Compliance in an Uncertain Enforcement Landscape
The amendments to the HIPAA Privacy Rule designed to protect reproductive health care information are under legal challenge as the compliance date quickly approaches.